Details of the Drug Combinations

General Information of This Drug (ID: DMALFKX)

• Drug Name: Savolitinib (DMALFKX)
• Synonyms: 1313725-88-0; AZD-6094; AZD6094; UNII-2A2DA6857R; CHEMBL3334567; 2A2DA6857R; Savolitinib [INN]; Volitinib(Savolitinib); Savolitinib [USAN:INN]; GTPL9918; SCHEMBL12489208; EX-A845; BDBM50023342; ZINC149738712; AKOS030526403; DB12048; compound 28 [PMID: 25148209]; HY-15959; AS-35250; 1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-; KB-333895; FT-0700162; J-690125; 4-{1-[(1S)-1-{imidazo[1,2-a]pyri

Indication

Renal cell carcinoma; ICD 11: 2C90; Status: Phase 3 [1]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 2 [2]

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Gefitinib + Savolitinib	DCFXTAY	Gefitinib	Non-Small Cell Lung Cancer	[3]
Rifampicin + Savolitinib	DCBRZ86	Rifampicin	Solid Tumors	[4]
Savolitinib + Famotidine	DCOD3O8	Famotidine	Solid Tumours	[5]
Savolitinib + Midazolam	DCSN0CY	Midazolam	Solid Tumors	[6]
Savolitinib + Itraconazole	DCX85H4	Itraconazole	Solid Tumour	[7]
Savolitinib + Docetaxel	DCZ3Q5H	Docetaxel	Gastric Cancer	[8]
Savolitinib + Docetaxel	DCG4HDO	Docetaxel	Advanced Gastric Adenocarcinoma	[9]
Savolitinib + Osimertinib	DCJ7UTK	Osimertinib	Non-Small Cell Lung Cancer	[10]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02127710) A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT02374645) A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
• [4] ClinicalTrials.gov (NCT04118842) A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin
• [5] ClinicalTrials.gov (NCT04179071) A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine
• [6] ClinicalTrials.gov (NCT04187456) A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body
• [7] ClinicalTrials.gov (NCT04121910) A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole
• [8] ClinicalTrials.gov (NCT02252913) A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer
• [9] ClinicalTrials.gov (NCT02447380) Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
• [10] ClinicalTrials.gov (NCT03944772) Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)